HIGHLIGHTS
SUMMARY
Pancreatic cancer represents the fourth leading cause of cancer death in the United_States with an estimated 48,220 pancreatic cancer-related deaths in 2021 which is driven in part by the highest case-fatality rate of any solid tumor malignancy. Traditionally, protein-based biomarkers (CEA and CA19-9) have served as adjuncts to CT imaging for assessing the response of patients to treatment, an Determine Correlation between CEA, CA19-9, cfDNA Biomarkers, and CT Response bloodstream by cancer cells. This tool has shown promise for the early identification of treatment response, recognition of disease . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.